Lackluster Amgen, Sanofi PCSK9 drugs could be under major threat from a new rival: analyst

It’s no secret that the two existing PCSK9 cardiovascular drugs on the market, Amgen’s Repatha and Regeneron and Sanofi’s Praluent, are suffering from painfully slow launches. And on top of that, they could soon face a serious threat thanks to a positive phase 3 readout from a more convenient option, one analyst argues.

The Medicines Company on Monday said its investigational cholesterol-lowering therapy, inclisiran, had hit the primary endpoint of a phase 3 trial.